Gynecology/Obstetrics and Neonatal
Neonatal Hyperbilirubinemia
November 2002
Clinical Focus*
Association of Neonatal Hyperbilirubinemia With Neurodevelopmental Outcomes
- What is the relationship between peak bilirubin levels and/or duration of hyperbilirubinemia and neurodevelopmental outcome?
- What is the evidence for effect modification of the results in the question above, by gestational age, hemolysis, serum albumin, and other factors?
Treatments for Neonatal Hyperbilirubinemia
- What are the quantitative estimates of efficacy of treatment at (1) reducing peak bilirubin levels (e.g., number needed to treat at 20 mg/dl to keep TSB from rising); (2) reducing the duration of hyperbilirubinemia (e.g., average number of hours by which time total serum bilirubin (TSB) greater than 20 mg/dl may be shortened by treatment); and (3) improving neurodevelopmental outcomes?
Diagnosis of Neonatal Hyperbilirubinemia
- What is the efficacy of various strategies for predicting hyperbilirubinemia, including hour-specific bilirubin percentiles?
- What is the accuracy of transcutaneous bilirubin (TcB) measurements?
*Addressed in the summary or evidence report.
Management of Neonatal Hyperbilirubinemia
Summary (Publication No. 03-E005, November 2002)
Evidence Report (Publication No. 03-E011, January 2003)
(File Download)
EPC: New England Medical Center
Topic Nominator: American Academy of Pediatrics
Return to Quick Menu: Evidence Report Topics
Return to Evidence-based Practice